Jun 29, 2026 07:02AM
Jun 29, 2026 07:00AM
Jun 23, 2026 06:50AM
Jun 11, 2026 07:02AM
Jun 11, 2026 07:00AM
May 12, 2026 04:05PM
May 5, 2026 07:00AM Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026
Mar 19, 2026 04:01PM
Mar 13, 2026 02:49PM
Mar 9, 2026 08:31AM
Mar 9, 2026 07:01AM
Mar 9, 2026 07:00AM
Mar 2, 2026 06:05AM
Jan 12, 2026 07:02AM Relmada gets FDA alignment on NDV-01 bladder cancer trial designs
Jan 12, 2026 07:00AM
Dec 22, 2025 12:49AM
Dec 21, 2025 08:00PM
Dec 3, 2025 07:30AM
Dec 3, 2025 07:30AM
Nov 13, 2025 04:01PM
Nov 4, 2025 07:01AM Relmada gets FDA backing for two NDV-01 bladder cancer trial paths
Nov 4, 2025 07:01AM
Oct 7, 2025 07:30AM
Oct 7, 2025 07:30AM
Sep 16, 2025 09:00AM
Sep 16, 2025 09:00AM
Sep 10, 2025 07:15AM
Sep 10, 2025 07:15AM Relmada Issues Mid-Year CEO Letter to Shareholders
Aug 7, 2025 04:05PM
Jul 15, 2025 08:02AM
Jul 15, 2025 08:00AM
Jun 17, 2025 07:00AM
May 12, 2025 04:01PM
Apr 28, 2025 01:39PM
Apr 28, 2025 01:38PM Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025
Apr 27, 2025 09:00AM
Apr 24, 2025 08:00AM
Apr 14, 2025 08:41AM
Apr 14, 2025 07:30AM
Mar 27, 2025 04:05PM
Mar 25, 2025 07:32AM
Mar 25, 2025 07:30AM Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.
Feb 6, 2025 07:30AM
Feb 6, 2025 07:30AM
Jun 18, 2024 08:31AM
Jun 18, 2024 08:30AM
Jan 9, 2023 08:01AM
Jan 9, 2023 08:00AM
Sep 20, 2022 08:30AM Relmada Therapeutics Announces Completion of Treatment in Company's Registrational Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for Major Depressive Disorder
Aug 11, 2022 04:15PM

325,893 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All